Statement: In total there were more adverse events in the secondary trial than in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 8/54 (14.81%)   Anaemia 1/54 (1.85%)   Febrile Neutropenia 1/54 (1.85%)   Retinopathy Hypertensive 1/54 (1.85%)   Febrile Infection 1/54 (1.85%)   Postoperative Wound Complication 1/54 (1.85%)   Cardiac Imaging Procedure Abnormal 1/54 (1.85%)   Malignant Melanoma In Situ 1/54 (1.85%)   Suicide Attempt 1/54 (1.85%)   Dyspnoea 1/54 (1.85%)
Secondary_evidence: Adverse Events 1:   Total: 3/6 (50.00%)   Febrile neutropenia 0/6 (0.00%)   Leukopenia 0/6 (0.00%)   Neutropenia 0/6 (0.00%)   Thrombocytopenia 0/6 (0.00%)   Cardio-respiratory arrest 0/6 (0.00%)   Cardiopulmonary failure 0/6 (0.00%)   Vertigo 0/6 (0.00%)   Visual impairment 0/6 (0.00%)   Abdominal pain 0/6 (0.00%)   Diarrhoea 0/6 (0.00%)   Dysphagia 0/6 (0.00%)   Gastric ulcer 0/6 (0.00%) Adverse Events 2:   Total: 6/17 (35.29%)   Febrile neutropenia 0/17 (0.00%)   Leukopenia 0/17 (0.00%)   Neutropenia 0/17 (0.00%)   Thrombocytopenia 0/17 (0.00%)   Cardio-respiratory arrest 1/17 (5.88%)   Cardiopulmonary failure 0/17 (0.00%)   Vertigo 0/17 (0.00%)   Visual impairment 0/17 (0.00%)   Abdominal pain 0/17 (0.00%)   Diarrhoea 1/17 (5.88%)   Dysphagia 0/17 (0.00%)   Gastric ulcer 1/17 (5.88%)